2nd Quarter - Report
VENN STRATEGIES for BIOMARIN PHARMACEUTICAL, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Firm
Income
$30,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 21, 2014 | $30,000 | Replaced |
| 2nd Quarter - Amendment | Jul 3, 2018 | $30,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Orphan drugs and rare diseases, matters related to drug reimbursement policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACK BAER | — |
| TIM CAREY | — |
| AMY L REDL | — |
| STEPHANIE SILVERMAN | — |
Taxation/Internal Revenue Code TAX
Tax policy affecting biopharmaceutical companies
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACK BAER | — |
| TIM CAREY | — |
| AMY L REDL | — |
| LAUREN RELIFORD | — |
| STEPHANIE SILVERMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.